Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VEGFR1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: VEGFR1. Displaying page 1 of 1.
    EudraCT Number: 2005-003209-10 Sponsor Protocol Number: ML18583 Start Date*: 2005-10-18
    Sponsor Name:Tampere University Hospital
    Full Title: VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
    Medical condition: FIGO Stage III-IV serous epithelial ovarian carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002700-21 Sponsor Protocol Number: OOI/Onkocytogenetika/2022/01 Start Date*: 2023-02-28
    Sponsor Name:National Institute of Oncology [...]
    1. National Institute of Oncology
    2. National Institute of Oncology
    Full Title: An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
    Medical condition: Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019121-34 Sponsor Protocol Number: E-3810-I-01 Start Date*: 2011-03-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase ...
    Medical condition: Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000975-21 Sponsor Protocol Number: RET-AFLI-2014-01 Start Date*: 2014-06-16
    Sponsor Name:Fundación Retinaplus +
    Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ...
    Medical condition: Macular edema secondary to central retinal vein occlusion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000848-26 Sponsor Protocol Number: BMF-AFLI-2013-01 Start Date*: 2013-07-04
    Sponsor Name:Barcelona Macula Foundation
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of ...
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000300-10 Sponsor Protocol Number: IDI-AFLI-2013-01 Start Date*: 2014-04-23
    Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL)
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study.
    Medical condition: Retinal angiomatous proliferation lesions (RAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018275-20 Sponsor Protocol Number: UMCNONCO201001 Start Date*: 2010-03-24
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
    Medical condition: symptomatic malignant ascites or pleural effusion
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025538 Malignant ascites LLT
    12.1 10026673 Malignant pleural effusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002445-36 Sponsor Protocol Number: 0001 Start Date*: 2011-10-31
    Sponsor Name:Department of Clinical Oncology, Leiden University Medical Center
    Full Title: Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study
    Medical condition: Hepatocellular carcinoma, not metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005201-48 Sponsor Protocol Number: 1199.93 Start Date*: 2013-07-16
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combina...
    Medical condition: Unresectable Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) GB (Completed) FR (Completed) DK (Completed) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Completed) PT (Completed) CZ (Completed) AT (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001180-11 Sponsor Protocol Number: ML20514 Start Date*: 2009-03-16
    Sponsor Name:Roche Pharma AG
    Full Title: An Open-label, single-arm, Phase II study to evaluate the efficacy and the feasibility of bevacizumab (Avastin®) based on a FOLFOXIRI regimen until progression in patients with previously untreated...
    Medical condition: previously untreated metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000427-27 Sponsor Protocol Number: VIPER-SHOCK Start Date*: 2017-03-30
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial
    Medical condition: Patients with septic shock admitted to the intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002834-35 Sponsor Protocol Number: PARERE Start Date*: 2020-09-24
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients.
    Medical condition: RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001426-26 Sponsor Protocol Number: A8471005 Start Date*: 2014-04-13
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A phase 2, randomized, open label study to evaluate the efficacy, safety, pharmacodynamics, pharmacokinetics of the anti-ALK-1 MAB PF-03446962 in combination with best supportive care vs. best supp...
    Medical condition: Advanced hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005648-25 Sponsor Protocol Number: PHRC/07-03/RENNES Start Date*: 2008-01-31
    Sponsor Name:C.H.U. de RENNES
    Full Title: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatiq...
    Medical condition: Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001326 Adrenal carcinoma LLT
    9.1 10001327 Adrenal carcinoma NOS LLT
    9.1 10038395 Renal carcinoma LLT
    9.1 10038396 Renal carcinoma recurrent LLT
    9.1 10038397 Renal carcinoma stage I LLT
    9.1 10038398 Renal carcinoma stage II LLT
    9.1 10038399 Renal carcinoma stage III LLT
    9.1 10038400 Renal carcinoma stage IV LLT
    9.1 10050076 Metastatic renal carcinoma LLT
    9.1 10001326 Adrenal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002841-39 Sponsor Protocol Number: GINECO-OV-222 Start Date*: 2013-10-07
    Sponsor Name:ARCAGY GINECO
    Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela...
    Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 04:13:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA